Janssen publishes Ph III results of Tremfya® (guselkumab) for psoriatic arthritis

Janssen published data from Ph III trials of Tremfya® (guselkumab) for the treatment of psoriatic arthritis.  Janssen reported that early skin and enthesitis responses predicted longer-term clinical response, including disease remission at week 52.